No human trial has tested the combination as of June 2026
Campbell KCM, Cosenza N, Meech R, et al
These preclinical data suggest unimolecular poly-pharmacology as an effective means to target multiple mechanisms contributing to obesity, and further implicate glucagon receptor activation as the differentiating factor between incretin receptor mono- or dual-agonists and triagonists
If healthcare organizations stay aligned, focus on access and chronic care redesign, use AI with discipline and operate as true systems, there's a real opportunity to shape what comes next not just react to it
By reducing tyrosinase activity, it shifts production from eumelanin (darker pigment) to pheomelanin (lighter pigment), resulting in a gradual lightening effect